Skip to main content
. 1997 Dec 9;94(25):14105–14110. doi: 10.1073/pnas.94.25.14105

Table 2.

Comparative effects on in vivo estrogen antagonism for various basic side chain modifications in the raloxifene nucleus

graphic file with name pq25720900t2.jpg

graphic file with name pq25720901t2.jpg

Compound     R In Vivo estrogen antagonism, maximal percent inhibition (Uterine wt/body wt)
Tamoxifen 48*
1 91*
1g 81*
1h 3.8
1i 10
1j 38*
1k 36*
*

Statistical significance relative to ethynyl estradiol-treated control (P ≤ 0.05).